Skip to main content
. 2021 Apr 15;131(8):e142906. doi: 10.1172/JCI142906

Figure 6. Combination therapy with α-mCD20 with α-mBAFF or mTACI-Fc in FVIII inhibitor mice.

Figure 6

(A) Schema for combination α-mCD20 and α-mBAFF or mTACI-Fc therapy. HA inhibitor mice were treated with α-mCD20 with α-mBAFF (red circles, n = 10), α-mCD20 with mTACI-Fc (purple diamonds, n = 8), or no treatment (black circles, n = 8) and followed for (B) Bethesda titer and (C) α-FVIII IgG1. At 16 weeks from start of regimen, spleens (D) and bone marrow (E) were harvested for quantification of plasmablasts and plasma cells by flow cytometry (values normalized per million lymphocytes). (F) FVIII-specific B cell ELISPOT from splenic and bone marrow plasma cells (conducted in triplicate from n = 4 mice per group), with representative images of samples (G). *P < 0.05; **P < 0.01; ***P < 0.001 by mixed-effects ANOVA (B and C) or 1-way ANOVA (D–F). NS, not significant.